Navigation Links
Top 100 Drug Sales Data Released - Plavix Leads the Way
Date:7/18/2012

NEW YORK, July 18, 2012 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2012 U.S. prescription sales data for the top 100 drugs.

Blood-thinners, proton-pump inhibitors, antipsychotics and asthma therapeutic categories continue to remain top sellers.

Top Five Drugs by Sales, Q1 2012 Drug Name

Sales ($000)

% Change (previous quarter)Plavix

1,620,790

2.85%Nexium

1,395,981

-3.08%Abilify

1,340,200

4.46%Singulair

1,238,134

8.67%Seroquel

1,161,141

3.29%Bristol-Myers Squibb's Plavix leads the way with over $1.6 billion in sales in the first quarter of 2012. However, the recent launch of clopidogrel (the generic version of Plavix) may alter these figures in upcoming quarters. Proton-pump inhibitor Nexium sees a small decline, while sales for Abilify and Singulair both exceeded $1 billion. The generic version of Singulair (montelukast) is slated for market entry in Q3 2012.

"The most recent sales data from the first quarter of 2012 highlights the continued stronghold of several branded medications," said Philip Thornton, CEO of Drugs.com. "However, with generic versions of Plavix and Lipitor now available and with a number of established brands moving to first-time generic status in the coming years, lower-cost medications will enable patients to have greater access to lifesaving treatments and save billions in healthcare dollars."

Top Sales Gains and Losses in Q1 2012Atorvastatin and its branded version Lipitor claim both the top gain and loss, respectively, in Q1 2012.

Q1 2012 Top Five Sales GainsDrug Name

Gain ($000)

% Changeatorvastatin

$447,316

+88.56%Synagis

$109,826

+38.30%Singulair

$98,833

+8.67%Remicade

$82,088

+10.04%Cymbalta

$72,540

+7.58%Atorvastatin makes the biggest gain, bringing total sales in Q1 2012 to $952 million. As a comparison, Lipitor sales reached $1.9 billion in each of the first three quarters of 2011.

Synagis, MedImmune's monoclonal antibody used for prevention of respiratory syncytial virus (RSV) in infants and young children, gains 38 percent.

Q1 2012 Top Five Sales LossesDrug Name

Loss ($000)

% ChangeLipitor

-760,948

-47.51%Lexapro

-227,560

-31.67%Zyprexa

-184,540

-49.69%Epogen

-159,223

-24.52%Incivek

-75,404

-16.88%Pfizer's cholesterol-lowering statin Lipitor lost patent protection in 2011 and sales of the brand dropped to 14th position.

Eli Lilly's Zyprexa drops 43 places to 84th and closes the quarter with $194 million. Sales of Forest Laboratories' popular antidepressant Lexapro also declined due to the availability of its generic counterpart, escitalopram.

Detailed data on the top 100 drugs can be accessed at: http://www.drugs.com/stats/top100/sales

About Drugs.comDrugs.com is the leading online drug information resource with over seven million unique visitors per month (ComScore, June 2012). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit: http://www.drugs.com/

Media Inquiries:

Drugs.com Press Officer
press@drugs.com
(718) 395 2473

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Drugs.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Industry Veteran Brings Sales Expertise to AlloSources Growing Distribution Network
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
4. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
5. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
6. SCOLR Pharma Welcomes Clem Calabrese as Director of Field Sales
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. Allied Healthcare Products Reports Loss on Sales Decline
9. Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry
10. Millennium Surgical Corp. Announces Sales Figures, Growth
11. Cephasonics Inks Distribution Deal With Tritech To Extend Worldwide Sales Reach Into Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):